Prospective, phase IIa, multicenter, open, non-controlled efficacy and tolerability of first-line therapy as a single agent eribulin in patients with HER2 negative metastatic breast cancer previously treated with taxanes
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2016
Price : $35 *
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms MERIBEL
- 11 Oct 2016 Results assessing efficacy and safety of Eribulin as first line therapy presented at the 41st European Society for Medical Oncology Congress
- 29 Sep 2016 According to Eisai media release, subanalyses from this study will be presented at the European Society for Medical Oncology (ESMO) Congress.
- 18 Mar 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.